Future TMJOA therapies could leverage eosinophil‐mediated immune modulation combined with natural adhesives, creating a stable repair environment and supporting cartilage regeneration by mimicking ECM‐like scaffolds.[88] Mast cells, derived from a GATA‐1+ progenitor shared with eosinophils,[89] release histamine, heparin, and chemotactic factors upon activation,[77, 90] mediating inflammation and tissue remodeling through degranulation.[91] Their altered distribution in peripheral osteoarthritis[22] suggests a potential role in joint disease pathogenesis. This evidence concerns the gene GATA1 and arthropathy.